Physician profile
Jenna Kish
NPI 1295270379
$2,521.84
in general payments reported to CMS, 2019-2025
38 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $205 · 2022: $822 · 2023: $466 · 2024: $729 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,080 · Education: $415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,079.83 |
| Education | $414.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $519.91 | 2021-2024 | |
| Incyte Corporation | $259.07 | 2022-2024 | Jakafi |
| Eisai INC. | $221.15 | 2022-2025 | |
| Janssen Biotech, INC. | $159.00 | 2022-2025 | Darzalex, Erleada, Talvey |
| Astrazeneca Pharmaceuticals LP | $127.95 | 2021-2023 | Imfinzi |
| Novartis Pharmaceuticals Corporation | $96.70 | 2021-2024 | |
| Celgene Corporation | $87.78 | 2021-2023 | Reblozyl, Pomalyst |
| Regeneron Healthcare Solutions, INC. | $72.54 | 2022-2023 | Libtayo |
| Abbvie INC. | $68.32 | 2024 | |
| Genzyme Corporation | $64.57 | 2022-2024 | |
| Glaxosmithkline, LLC. | $60.15 | 2022-2025 | Jemperli, Ojjaara |
| Amgen INC. | $53.57 | 2021-2022 | |
| Daiichi Sankyo INC. | $50.30 | 2021-2022 | |
| Pharmaessentia USA Corporation | $49.93 | 2025 | Besremi |
| E.R. Squibb & Sons, L.L.C. | $47.29 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Kish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.